After the close Friday, ImmunoGen, Inc. (Nasdaq: IMGN) announced the presentation of encouraging initial efficacy, safety and tolerability clinical data ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE